Loading...
•
Sep 30, 2021
Adaptimmune Q3 2021 Earnings Report
Adaptimmune reported financial results and business update for Q3 2021.
Key Takeaways
Adaptimmune made significant strides in Q3 with encouraging SURPASS trial data, the initiation of a Phase 2 trial with ADP-A2M4CD8, and the announcement of a strategic collaboration with Genentech. The company's cash, cash equivalents, and marketable securities, along with upfront payments from Genentech, are expected to fund operations into early 2024.
Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment.
SURPASS trial data at ESMO confirms potential of MAGE-A4 franchise across a range of tumors: overall response rate of 36% and 86% disease control rate with responses in five different solid tumors.
Initiated Phase 2 SURPASS-2 trial investigating next-generation ADP-A2M4CD8 in patients with esophageal and EGJ cancers.
Financial guidance confirmed: funded into early 2024.
Forward Guidance
Adaptimmune believes that its existing cash, cash equivalents and marketable securities, together with the upfront and exclusivity payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company’s current operations into early 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...